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1. Introduction  
Oxidative DNA damage is one of the earliest detectable events in several neurodegenerative 
diseases, often preceding the onset of the clinical symptoms. Moreover, neurons in the adult 
human brain can re-enter the cell division cycle, likely allowing DNA repair. Impairments of 
DNA repair pathways are reported in neurons of patients suffering from one of several 
neurodegenative diseases and might result in the accumulation of mutations critical for 
neurodegeneration. Current investigation aims at understanding the causes of such 
impairment (Coppedè & Migliore, 2010). One of the most robust set of data that 
demonstrates association between DNA repair and neurodegenerative diseases comes from 
studies on early onset ataxia with ocular motor apraxia and hypoalbuminemia/ataxia with 
oculomotor apraxia type 1 (EAOH/AOA1), an autosomal recessive form of cerebellar ataxia 
caused by mutations in the aprataxin (APTX) gene. It was shown that aprataxin participates 
in DNA repair suggesting that genes involved in DNA repair pathways might have a role in 
neurodegeneration (Hirano et al., 2007; Takahashi et al., 2007). Also parkin, encoded by one 
of the causative genes of Parkinson’s disease (PD), seems to contribute to DNA repair (Kao, 
2009). Variants and polymorphisms of DNA repair genes, particularly DNA base excision 
repair (BER) genes, have been investigated as possible risk factors for Alzheimer’s disease 
(AD), Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and other neurodegenerative 
diseases (Coppedè & Migliore, 2010). There is also evidence that BER could contribute to 
CAG repeat expansion in Huntington’s disease (HD) (Kovtun et al., 2007). Most of the 
genetic association studies have been performed in the last few years and gave often 
conflicting or inconclusive results, their power was limited by the sample size of case-
control groups, gene-gene interactions were missing, and only common polymorphisms 
have been included with little or no attention paid to rare gene variants (Coppedè, 2011). In 
this chapter I discuss the current knowledge on DNA repair gene variants and 
polymorphisms and major neurodegenerative disorders. 
2. DNA repair pathways 
A brief overview of the major DNA repair pathways in mammals is shown in Table 1. It is 
estimated that our cells are subjected to a daily average of about one million lesions that, if 
not properly repaired, can drive mutagenesis, disrupt normal gene expression or create 
aberrant protein products. Cells have therefore developed several repair systems that can be 
www.intechopen.com
 
DNA Repair 
 
568 
generally divided into single stand break (SSB) and double strand break (DSB) repair 
pathways (Table 1).  
 
Pathway Type of repair Type of damage 
Base excision repair 
(BER) 
SSB Modifications of DNA bases due to 
oxidation, alkylation, and deamination 
 
Nucleotide excision 
repair (NER) 
SSB 
 
Repair of UV photoproducts, DNA 
crosslinks, and bulky lesions. 
 
Mismatch repair 
(MMR) 
SSB 
 
Repair of mismatches and small insertions 
or deletions during replication. 
 
Homologous 
recombination (HR) 
DSB Repair of DNA DSBs, such as those caused 
by ionizing radiations, through 
recombination with regions of homology 
(usually a sister chromatid) during late S or 
G2 phases of the cell cycle 
 
Non homologous end 
joining (NHEJ) 
DSB Repair of DNA DSBs, such as those induced 
by radiations, without recombination with 
regions of homology; it occurs during G0, 
G1, and early S phases of the cell cycle 
Table 1. Major DNA repair pathways in mammalian cells 
2.1 Base excision repair (BER) 
The DNA base excision repair pathway deserves a detailed description since it is believed to 
be the major pathway for repairing DNA base modifications caused by oxidation, 
deamination and alkylation. DNA glycosylases catalyze the first step in the BER process by 
cleaving the N-glycosylic bond between a damaged base and the sugar moiety; after the 
cleavage the damaged base is released resulting in the formation of an abasic site which is 
then cleaved by an AP lyase activity or by the major mammalian apurinic/apyrimidinic 
endonuclease (APEX1).  Repair can then proceed through short or long-patch BER. In short-
patch BER, which is the most common sub-pathway, a single nucleotide is incorporated into 
the gap by DNA polymerase ǃ (Pol ǃ) and ligated by the DNA ligase III/ X-ray repair cross-
complementing group 1 (XRCC1) complex. In long-patch BER several nucleotides (two to 
seven-eight) are incorporated, followed by cleavage of the resulting 5’ flap structure and 
ligation. It has been suggested that after Pol ǃ adds the first nucleotide into the gap, it is 
substituted by Pol ǅ/ǆ which continues long-patch BER. DNA ligase I completes the long-
patch pathway. Several other proteins, including the proliferating cell nuclear antigen 
(PCNA), the RPA protein, and the 5’-flap endonuclease (FEN-1) participate in long-patch 
BER. Recent evidence suggests that XRCC1 acts as a scaffold protein in short-patch BER, 
regulating and coordinating the whole process. XRCC1 recruits DNA Pol ǃ and DNA ligase 
III required for filling and sealing the damaged strand. Moreover, it also interacts with 
DNA glycosylases and APEX1, mediating their exchange at the damaged site. XRCC1 also 
interacts with PARP-1, which is one of the cellular sensors of DNA SSBs and DSBs. BER 
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takes places either in nuclei and mitochondria, and mitochondria have independent BER 
machinery encoded by nuclear genes. Indeed, several BER enzymes have been identified 
which have both nuclear and mitochondrial forms. The gaps generated by the action of 
AP endonucleases/lyases are filled in by Pol Ǆ in the mitochondria, and ligation is 
mediate by ligase III. To date, there is no evidence of long-patch BER in mitochondria 
(Weissman et al., 2007). 
2.2 Nucleotide excision repair (NER) 
The nucleotide excision repair pathway (NER) is required for the removal of a wide variety 
of forms of DNA damage, including UV induced photoproducts, DNA crosslinks, and other 
bulky lesions.  NER involves at least 20-30 proteins or complexes of proteins, and is divided 
into global genome repair (GGR) and transcription coupled repair (TCR). The two pathways 
mainly differ in the initial steps that recognize the DNA lesion, and different initial 
recognition factors are involved. NER senses the presence of a lesion through the distortion 
it causes to the DNA structure. In GGR DNA damage recognition requires the xeroderma 
pigmentosum (XP) complementing protein XPC-HR23B-centrin complex. The DNA 
damage is verified by opening of the DNA strands surrounding the lesion by the 
transcription factor TFIIH. This is followed by recruitment of XPA and other components 
of the transcription factor TFIIH to the lesion site. In TCR the recognition step is initiated 
when a RNA polymerase stalls at a lesion site and requires the Cockayne’s syndrome 
proteins CSA and CSB. After a correct assembly of the NER complex, a fragment of 24-32 
nucleotides is incised and removed from the damaged strand by the simultaneous action 
of the DNA excision repair cross complementing (ERCC) proteins ERCC5 (XPG; 3’ 
endonuclease) and ERCC4 (XPF; 5’ endonuclease) complexed with ERCC1. Repair is 
completed by new DNA synthesis mediated by DNA Pol ǅ/ǆ, DNA Pol κ, and ligation 
(DNA ligase I, DNA ligase III) of the nascent DNA to the parental strands using the 
undamaged strand as a template. The GGR pathway removes damages overall in the 
genome irrespective of genome location and point in the cell cycle, whereas TCR is 
required for the specific repair of bulky lesions in the transcribed strand of active genes. 
Mitochondria have been shown to lack NER, which operates in the nucleus removing the 
majority of DNA lesions (Fleck & Nielsen, 2004; Subba Rao, 2007).   
2.3 Mismatch repair (MMR) 
Mismatch repair (MMR) corrects mismatches and small insertions or deletions during DNA 
replication, thus eliminating potentially pre-mutagenic bases. Repair involves recognition of 
the mismatch by MutSǂ (MSH2 and MSH6 proteins), or by MutSβ (MSH2 and MSH3 
proteins) in the case of small insertions/deletions (1-10 nucleotides). MutLǂ (a heterodimer 
of MLH1 and PMS2 proteins) is then recruited and serves to coordinate the process that 
involves, among others, the PCNA protein for strand discrimination and exonuclease 1, 
DNA Pol ǅ and a DNA ligase, for DNA repair (Kunkel & Erie, 2005).  
2.4 Homologous recombination (HR) and non homologous end joining (NHEJ) 
Non homologous end joining (NHEJ) is the major pathway for the repair of DSBs because it 
can function throughout the cell cycle and does not require a homologous chromosome. 
Rather, NHEJ involves rejoining of what remains of the two DNA ends, tolerating 
nucleotide loss or addition at the rejoining site. When a DSB occurs during G0, G1, and early 
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S phase, the Ku heterodimer (Ku70/Ku80) recognizes DSB ends, aligns them, protects them 
from excessive degradation, and ultimately prepares them for ligation. The Ku heterodimer 
is capable of interacting with the nuclease (Artemis-DNA-PKcs) complex, the polymerases 
(µ and λ), and the ligase (XLF-XRCC4-DNA ligase IV) complex. If complementary ends are 
not present at the break, the Artemis-DNA-PKcs complex resects some of the overhangs to 
create single-strand overhangs with short stretches of micro-homology. When necessary, 
polymerization of missing nucleotides is performed by DNA polymerases. Then, the XLF-
XRCC4-LigaseIV complex seals the DSB. When homologous recombination (HR) is used for 
repair, it is promoted by the recombinase RAD51, the human homolog of the E. coli RecA 
protein, which binds to 3′-tailed single strands at the end of DSBs in a helical fashion and 
promotes pairing with homologous DNA sequences (usually the sister chromatid) as a 
prelude to strand invasion and repair of the DSBs. Strand invasion is the invasion of the 3′ 
end of the single-stranded DNA overhang into the region of complementarity in the intact 
sister chromatid. The process is directed by RAD51 which forms a nucleoprotein filament 
that directs homology search, strand pairing, and invasion of the homologous chromosome. 
Rad51 is assisted in this process by several RAD family members (RAD51B, RAD51C, 
RAD51D, XRCC2, XRCC3, RAD54, and RAD52). During strand invasion, RAD51 creates a 
four-stranded Holliday junction intermediate. Then, the invading strand is extended by 
DNA polymerase η and the Holliday junction is resolved by a RAD51C and XRCC3 directed 
mechanism. Several nucleases and helicases, such as the RecQ family members, also 
participate in resolving Holliday junctions. Since eukaryotic genomes contain dispersed 
repeated DNA, repair of DSBs by HR can occur not only through an interaction with the 
sister chromatid or the homolog chromosome, but also with repeats on non-homolog 
chromosomes. Numerous factors affect the decision to repair a DSB via these pathways, and 
accumulating evidence suggests these major repair pathways both cooperate and compete 
with each other at double-strand break sites to facilitate efficient repair and promote 
genomic integrity (Kass & Jasin, 2010).  
3. Polymorphisms of DNA repair genes and Alzheimer’s disease 
Alzheimer's disease is a complex multi-factorial neurodegenerative disorder and 
represents the most common form of dementia in the elderly. In 2006, the worldwide 
prevalence of AD was 26.6 million. It has been estimated that following the global aging 
of the world’s population this number will quadruple by 2050, suggesting that 1 in 85 
persons worldwide will be living with the disease, which is clinically characterized by a 
progressive neurodegeneration in selected brain regions, including the temporal and 
parietal lobes and restricted regions within the frontal cortex and the cingulate gyrus, 
resulting in gross atrophy of the affected regions and leading to memory loss 
accompanied by changes of behaviour and personality severe enough to affect work, 
lifelong hobbies or social life (Brookmeyer et al., 2007). Increasing evidence reports 
oxidative DNA damage in affected brain regions of AD patients, paralleled by a decrease 
in DNA repair activities, particularly concerning the BER pathway (Lovell et al., 2000; 
Weissman et al., 2007). This has driven current research to focus on common 
polymorphisms of BER genes as candidate AD risk factors. Studied genes are those 
encoding for 8-oxoguanine DNA glycosylase (OGG1), APEX1 and XRCC1. Particularly, 
we screened 178 Italian late onset AD patients and 146 matched controls for the presence 
of the OGG1 Ser326Cys gene polymorphism (rs1052133), observing no difference in allele 
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and genotype frequencies between patients and controls (Coppedè et al., 2007a). 
Subsequently, 91 sporadic Turkish AD patients and 93 matched controls have been 
genotyped for the presence of OGG1 Ser326Cys, APEX1 Asp148Glu (rs1130409), XRCC1 
Arg280His (rs25489) and XRCC1 Arg399Gln (rs25487) polymorphisms, but none of them 
was associated with increased AD risk (Parildar-Karpuzoğlu et al. 2008). Also a small 
case-control study performed in Poland with 41 AD patients and 51 controls failed to find 
significant differences in OGG1 Ser326Cys allele frequencies between groups (Dorszewska 
et al., 2009). A borderline association with AD risk (P =0.06) was observed for the XRCC1 
Arg194Trp (rs1799782) polymorphism in a group of 98 Turkish AD patients and 95 
healthy subjects (Doğru-Abbasoğlu et al., 2007), but a recent study failed to replicate this 
association in a larger case-control group of over 200 Chinese AD patients (Quian et al., 
2010). Overall, five common functional polymorphisms of BER genes have been 
investigated as possible AD risk factors, but none of them resulted significantly associated 
with increased AD risk (Table 2). Also polymorphisms of NER genes have been evaluated 
as candidate AD risk factors. Particularly, two common polymorphisms of the XPD 
(ERCC2) gene (namely, rs238406 and rs13181), and a silent mutation in exon 11 (T>C at 
codon 824) of the XPF (XRCC4) gene have been investigated in 97 Turkish AD patients 
and in 101 matched controls, but none of them resulted to be associated with AD risk 
(Doğru-Abbasoğlu et al., 2006). Poly-ADP-ribose polymerase-1 (PARP-1) is a zinc-finger 
DNA binding protein that is activated by DNA SSBs or DSBs. The primary function of 
PARP-1 is in DNA repair processes through the detection of DNA damage and the 
prevention of chromatide exchanges. PARP-1 poly-ADP-ribosylates several proteins 
involved in DNA repair including histones, thus inducing local relaxation of the 
chromatin structure and facilitating the access of repair proteins to damaged DNA. There 
is evidence for widespread DNA SSBs and DSBs in AD brains, as well as increased PARP-
1 activity (Love et al., 1999). Two independent groups evaluated PARP-1 gene 
polymorphisms as putative AD risk factors. Infante and coworkers screened 263 Spanish 
AD patients and 293 matched controls for the presence of two PARP-1 promoter 
polymorphisms (–410 and –1672). If evaluated independently, nor PARP-1 –410 neither 
PARP-1 –1672 resulted associated with increased AD risk (Table 2). However, PARP-1 –
410 and PARP-1 –1672 polymorphisms resulted in linkage disequilibrium and some 
haplotypes were associated with increased AD risk. Particularly, haplotypes 2-1 and 1-2 
were significantly overrepresented in AD individuals and associated with an increased 
risk for the disease with an adjusted OR of 1.42 and 5.38, respectively (Infante et al., 2007). 
More recently two PARP-1 exonic polymorphisms, 414C>T (rs1805404) and 2456T>C 
(rs1136410), have been evaluated in 120 Chinese AD patients and 111 matched controls 
(Liu et al., 2010). Again, none of the polymorphisms resulted independently associated 
with increased AD risk (Table 2). However, authors found that the distributions of 
haplotype 3-TT and haplotype 4-CC were significantly associated with an increased risk 
of AD, whereas the haplotype 1-TC showed a protective effect, with OR of 12.2 and 0.52, 
respectively (Liu et al., 2010). Overall, both studies support the hypothesis that PARP1 
haplotypes might affect AD risk. 
3.1 Searching for BER gene variants in DNA extracted from post-mortem AD brain 
Mao and colleagues extracted nuclear DNA from post-mortem brain specimens of 14 late 
stage AD patients and 10 neurologically healthy controls. They identified and characterized 
novel OGG1 mutations (a single base deletion C796del, and two base substitutions leading 
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Reference Polymorphism 
Number of 
subjects 
AD/Controls 
Variant allele 
frequency 
AD/Controls 
Odds Ratio 
(95% CI) 
Coppedè et 
al., 2007a 
OGG1 Ser326Cys 178/146 0.19/0.18 1.04 (0.70-1.55) 
Parildar-
Karpuzoğlu 
et al. 2008 
OGG1 Ser326Cys 91/93 0.29/0.23 1.32 (0.83-2.11) 
Dorszewska 
et al., 2009 
OGG1 Ser326Cys 41/51 0.29/0.21 1.60 (0.81-3.14) 
Parildar-
Karpuzoğlu 
et al. 2008 
APEX1 
Asp148Glu 
91/93 0.33/0.31 1.08 (0.70-1.68) 
Parildar-
Karpuzoğlu 
et al. 2008 
XRCC1 
Arg280His 
91/93 0.06/0.10 0.53 (0.24-1.14) 
Parildar-
Karpuzoğlu 
et al. 2008 
XRCC1 
Arg399Gln 
91/93 034/0.33 1.05 (0.68-1.63) 
Doğru-
Abbasoğlu et 
al., 2007 
XRCC1 
Arg194Trp 
98/95 0.11/0.06 2.06 (0.97-4.37) 
Quian et al., 
2010 
XRCC1 
Arg194Trp 
212/203 0.31/0.31 1.04 (0.70-1.52) 
Doğru-
Abbasoğlu et 
al., 2006 
ERCC2 rs238406 
(XPD exon 6) 
97/101 0.40/0.42 0.94 (0.63-1.41) 
Doğru-
Abbasoğlu et 
al., 2006 
ERCC2 rs13181 
(XPD exon 23) 
97/101 0.41/0.36 1.24 (0.83-1.86) 
Doğru-
Abbasoğlu et 
al., 2006 
ERCC4 
(XPF exon 11) 
97/101 0.37/0.35 1.09 (0.72-1.64) 
Infante et al., 
2007a 
PARP-1 
(-410) 
263/293 0.35/0.33 1.08 (0.84-1.38) 
Infante et al., 
2007a 
PARP-1 
(-1672) 
263/293 0.17/0.18 0.94 (0.69-1.27) 
Liu et al., 
2010 
PARP-1 
(rs1805404) 
120/111 0.53/0.59 0.76 (0.53-1.11) 
Liu et al., 
2010 
PARP-1 
(rs1136410) 
120/111 0.52/0.59 0.75 (0.52-1.09) 
Table 2. DNA repair gene polymorphisms and risk of Alzheimer’s disease 
to Ala53Thr or Ala288Val amino acidic changes, respectively) in 4 of 14 AD subjects. 
Particularly, two AD patients carried the C796 deletion, one patient had the Ala53Thr 
substitution, and another patient carried the Ala288Val substitution. No mutations were 
found in any of 10 studied age-matched controls (Mao et al., 2007). This study is not an 
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association study for risk assessment but a genetic screening performed on brain DNA 
specimens searching for novel OGG1 variants. The authors created the mutant proteins by 
site-directed mutagenesis observing that the C796del mutant OGG1 lacks glycosylase 
activity, whereas both Ala53Thr and Ala288Val substitutions result in 40–50% reduced 
activity (Mao et al., 2007). Therefore, we cannot exclude that the activity of the OGG1 
protein might be partially impaired by rare gene variants in some AD subjects. However, 
given the limited sample-size of the studied case-control group, further studies are required 
to confirm this hypothesis. 
4. Polymorphisms of DNA repair genes and amyotrophic lateral sclerosis 
Amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND), is one of 
the major neurodegenerative diseases alongside AD and PD. It is a progressive disorder 
characterized by the degeneration of motor neurons of the motor cortex, brainstem and 
spinal cord. The incidence of the disease is similar worldwide and ranges from 1 to 3 cases 
per 100,000 individuals per year, with the exception of some high-risk areas around the 
Pacific Rim. Several studies report increased oxidative DNA damage and a compromised 
DNA repair activity, particularly BER activity, in spinal cords and other tissues of ALS 
patients (Bogdanov et al., 2000; Ferrante et al., 1997; Kikuchi et al., 2002; Kisby et al., 1997). 
Missense mutations in the gene encoding APEX1 were found in DNA obtained from 8 of 11 
ALS patients, including the common APEX1 Asp148Glu polymorphism (Hayward et al., 
1999), that was subsequently associated with increased ALS risk in a Scottish cohort of 117 
ALS patients and 58 controls, and in an Irish group of 105 ALS individuals and 82 controls 
(Greenway et al., 2004). The analysis of 88 English ALS patients and 88 matched controls still 
revealed an increased frequency of the variant allele in the ALS cohort, even if not 
statistically significant (Tomkins et al. 2000). We have recently performed the largest case-
control study aimed at clarifying the role of APEX1 Asp148Glu in sporadic ALS 
pathogenesis. No difference in APEX1 Asp148Glu allele and genotype frequencies was 
found between 134 ALS patients and 129 controls of Italian origin, nor was the 
polymorphism associated with disease age or site of onset, or duration of the disease, 
suggesting that it might not play a major role in ALS pathogenesis in the Italian population 
(Coppedè et al., 2010a). The ALSGene database (www.alsgene.org) is a public database 
containing all the ALS genetic association studies, genome-wide association studies and 
updated meta-analyses of the literature. A meta-analysis of the four studies described above 
revealed a significant increased frequency of the variant 148Glu allele in ALS cases with 
respect to controls, suggesting a protective role for the wild type 148Asp variant with an OR 
= 0.78 (95%CI=0.62-0.97) (www.alsgene.org). Our analysis of the OGG1 Ser326Cys 
polymorphism in 136 ALS patients and 129 matched controls of Italian origin revealed a 
significant association of the variant allele with increased ALS risk (Coppedè et al., 2007b) 
(Table 3). At best of our knowledge this study is the first in the literature addressing this 
issue, still pending replication in other populations. More recently, we screened over 400 
individuals, including 206 ALS patients and 203 matched controls of Italian origin for the 
presence of XRCC1 Arg194Trp, Arg280His and Arg399Gln polymorphisms, observing a 
significant increased frequency of the 399Gln variant allele and a borderline significant 
decreased frequency of the 194Trp allele in ALS patients with respect to controls (Coppedè 
et al., 2010b). Interestingly, others have evaluated the same XRCC1 polymorphisms and two 
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additional ones (rs939461 and rs915927) in 108 ALS patients and 39 controls from New-
England, observing that rs939461 was associated with reduced ALS risk, and Arg399Gln 
with a borderline significant reduced risk (Fang et al., 2010) (Table 3). Overall, even if still 
inconclusive, the results of both studies suggest that additional investigation is required to 
clarify the role of XRCC1 polymorphisms and haplotypes in ALS pathogenesis. 
4.1 Less frequent BER gene variants and polymorphisms 
Alongside with common BER gene polymorphisms, less frequent gene variants or 
polymorphisms have been observed in the DNA of both ALS subjects and matched controls, 
but with very low allele frequencies and no significant difference between groups. Some 
examples are APEX1 1835C/A (Intron3), APEX1 2712A/T (3'UTR), APEX1 459C/T (Exon1), 
and APEX1 rs1048945 (Q51H) (Hayward et al., 1999; Tomkins et al., 2000). 
 
Reference Polymorphism 
Number of 
subjects 
ALS/Controls 
Variant allele 
frequency 
ALS/Controls 
Odds Ratio 
(95% CI) 
Coppedè et al., 
2007b 
OGG1 
Ser326Cys 
136/129 0.26/0.18 1.62 (1.07-2.45) 
Hayward et al. 
1999 
APEX1 
Asp148Glu 
117/58 0.62/0.49 1.66 (1.06-2.60) 
Tomkins et al. 
2000 
APEX1 
Asp148Glu 
88/88 0.51/0.45 1.28 (0.85-1.95) 
Greenway et al. 
2004 
APEX1 
Asp148Glu 
105/82 0.60/0.51 1.46 (0.97-2.21) 
Coppedè et al. 
2010a 
APEX1 
Asp148Glu 
134/129 0.44/0.45 0.99 (0.70-1.40) 
Coppedè et al. 
2010b 
XRCC1 
Arg194Trp 
206/195 0.05/0.08 0.58 (0.32-1.05) 
Coppedè et al. 
2010b 
XRCC1 
Arg280His 
205/203 0.09/0.08 1.25 (0.76-2.04) 
Coppedè et al. 
2010b 
XRCC1 
Arg399Gln 
197/194 0.39/0.28 1.39 (1.05-1.85) 
Fang et al. 2010 
XRCC1 
Arg194Trp 
108/39 0.06/0.03 2.4 (0.5-2.2)a 
Fang et al. 2010 
XRCC1 
Arg280His 
108/39 0.05/0.03 2.0 (0.4-2.0)a 
Fang et al. 2010 
XRCC1 
Arg399Gln 
108/39 0.35/0.47 0.4 (0.2-1.0)a 
Fang et al. 2010 
XRCC1 
rs915927 
108/39 0.45/0.33 2.4 (0.5-2.2)a 
Fang et al. 2010 
XRCC1 
rs939461 
108/39 0.06/0.15 0.4 (0.1-0.9)a 
Table 3. DNA repair gene polymorphisms and risk of Amyotrophic Lateral sclerosisa  OR are 
derived from the original paper and referred to (heterozygous+minor homozygous) vs 
major homozygous. 
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5. Polymorphisms of DNA repair genes and Parkinson’s disease 
Parkinson’s disease is the second most common neurodegenerative disorder after AD, 
affecting 1–2% of the population over the age of 50 years, and is characterized by 
progressive and profound loss of neuromelanin containing dopaminergic neurons in the 
substantia nigra (SN) resulting in resting tremor, rigidity, bradykinesia, and postural 
instability. The majority of PD cases are sporadic idiopathic forms, resulting from three 
interactive events: an individual’s inherited genetic susceptibility, subsequent exposure to 
environmental risk factors, and aging (Bekris et al., 2010). However, in a minority of the 
cases PD is inherited as a Mendelian trait. Parkin is an E3 ubiquitin ligase that acts on a 
variety of substrates, resulting in polyubiquitination and degradation by the proteasome 
or monoubiquitination and regulation of biological activity. Mutation of parkin is one of 
the most prevalent causes of autosomal recessive familial PD and a recent study has 
shown that parkin is essential for optimal repair of DNA damage. Particularly, DNA 
damage induces nuclear translocation of parkin leading to interactions with PCNA and 
possibly other nuclear proteins involved in DNA repair (Kao, 2009). Moreover, parkin 
protects mitochondrial genome integrity and supports mitochondrial DNA (mtDNA) 
repair (Rothfuss et al., 2009). DNA polymerase gamma (POLG1) participates in mtDNA 
replication and repair, thus playing a fundamental role in mtDNA maintenance.  Missense 
mutations in POLG1 co-segregate with a phenotype that includes progressive external 
ophthalmoplegia and parkinsonism (Hudson et al., 2007). Moreover, missense mutations 
in POLG1 have been reported in case studies, in which parkinsonism was part of the 
clinical symptoms (Davidzon et al., 2006; Remes et al., 2008). POLG1 mutations and 
polymorphisms have been also investigated in sporadic idiopathic PD, among them a 
polyglutamine (poly-Q) located in the N-terminal of POLG1, encoded by a CAG repeat in 
exon 2. The poly-Q tract normally consists of 10Q (frequency >80%), followed by 11Q 
(frequency > 6-12%), whereas non-10Q/11Q alleles are considered as less frequent alleles. 
Several authors investigated whether or not non-10Q alleles are more frequent in PD cases 
than in matched controls (Hudson et al., 2009; Luoma et al., 2007; Taanman & Shapira, 
2005; Tiangyou et al., 2006). Eerola and coworkers recently screened 641 PD patients and 
292 controls from USA and performed a pooled analysis of their data with those available 
in the literature (Hudson et al., 2009; Luoma et al., 2007; Taanman & Shapira, 2005; 
Tiangyou et al., 2006) for a total of 1163 sporadic PD patients and 1214 controls observing 
that variant alleles defined as non-10Q were significantly increased in PD patients than in 
controls (16.3%vs.13.4%, p = 0.005) (Eerola et al., 2010). A few months later Anvret and 
coworkers screened 243 PD patients and 279 matched controls from Sweden, observing 
that non10Q/11Q alleles were more frequent in PD cases than in controls with an OR of 
2.0 (1.3-3.1, 95%CI) strengthening the evidence that non frequent POLG1 alleles might be 
more frequent in sporadic PD patients than in controls, thus representing a PD risk factor 
(Anvret et al., 2010) (Table 4). We screened 139 sporadic PD patients and 211 healthy 
matched controls for the presence of the OGG1 Ser326Cys polymorphism. The Cys326 
allele frequency was similar between the groups (0.20 in PD patients and 0.19 in controls), 
and no difference in genotype frequencies was observed. Moreover, the OGG1 Ser326Cys 
polymorphism was not associated with PD age at onset (Coppedè et al., 2010c). In human 
cells the oxidized purine nucleoside triphosphatase MTH1 efficiently hydrolyzes oxidized 
purines such as 8-oxo-guanine in the nucleotide pools, thus avoiding their incorporation 
into DNA or RNA. A Val83Met polymorphism of the MTH1 gene was studied in 73 
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Japanese patients with sporadic PD and 151 age-matched controls but was not associated 
with sporadic PD risk (Satoh & Kuroda, 2000). Another MTH1 polymorphism (Ile45Thr) 
was investigated in 106 PD patients and 135 unrelated controls from China.  The variant 
allele frequency resulted borderline increased in PD males (Jiang et al., 2008). This finding 
is pending replication in other populations. PARP1 promoter polymorphisms (-410C/T, -
1672G/A, and a (CA)n microsatellite) have been investigated in 146 Spanish PD cases and 
161 matched controls. A protective effect against PD was found for heterozygosity at  
-410 (OR = 0.44) and (CA)n microsatellite (OR = 0.53) polymorphisms, and heterozygosity 
at -1672 polymorphism delayed by 4 years on the onset age of PD (Infante et al., 2007). 
Also these findings are original and waiting for replication in additional case-control 
groups (Table 4). 
 
Reference Polymorphism 
Number of 
subjects 
PD/Controls 
Variant allele 
frequency 
PD/Controls 
Odds Ratio 
(95% CI) 
Eerola et 
al., 2010 
POLG1 
Poly-Q tract 
641/292 0.17/0.12 
OR = n.a. 
P = 0.004 
Eerola et 
al., 2010 
POLG1 
Poly-Q tract 
1163/1214a 0.16/0.13 
OR = n.a. 
P = 0.005 
Anvret et 
al., 2010 
POLG1 
Poly-Q tract 
243/279 0.11/0.06 2.0 (1.3-3.1) 
Coppedè et 
al., 2010c 
OGG1 
Ser326Cys 
139/211 0.20/0.19 1.05 (0.72-1.53) 
Satoh  &  
Kuroda, 
2000 
MTH1 
Val83Met 
73/151 0.07/0.11 
OR = n.a. 
P = 0.219 
Jiang et al., 
2008 
MTH1 
Ile45Thr 
106/135 0.05/0.02 
OR = n.a. 
P = 0.08b 
Infante et 
al., 2007b 
PARP-1 
(-410) 
146/161 0.35/0.53c 0.44 (0.26-0.75) 
Infante et 
al., 2007b 
PARP-1 
(-1672)d 
146/161 0.29/0.27c 0.87 (0.50-1.52) 
Infante et 
al., 2007b 
PARP-1 
(CA)n 
146/161 0.36/0.50c 0.53 (0.31-0.90) 
Table 4. DNA repair gene polymorphisms and risk of Parkinson’s disease. a = pooled-
analysis of (Eerola et al., 2010, Hudson et al., 2009; Luoma et al., 2007; Taanman & Shapira, 
2005; Tiangyou et al., 2006). b = Allele frequency difference (PD/Controls) approached 
significance in the male subgroup (0.07/0.02, P = 0.05). c = Heterozygous genotype 
frequency. d = Associated with PD age at onset 
5.1 Other mutations and polymorphisms 
As previously observed, several POLG1 mutations have been observed to co-segregate in 
families with parkinsonism. For a detailed description I suggest a recent review by Orsucci 
and coworkers (Orsucci et al., 2010).  
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6. Other neurodegenerative diseases 
6.1 Spinocerebellar ataxias  
Hereditary ataxias are a heterogeneous group of diseases with different patterns of 
inheritance. Some of them are caused by recessive mutations in genes involved in DNA 
repair pathways that likely predispose the affected individuals to neurodegeneration. 
Spinocerebellar ataxia with axonal neuropathy 1 (SCAN1) is caused by autosomal recessive 
mutations in the gene encoding tyrosyl-DNA phosphodiesterase 1 (TDP1), a protein 
required for the repair of DNA SSBs that arise independent of DNA replication from 
abortive topoisomerase 1 activity or oxidative stress. Ataxia-telangiectasia (AT), ataxia-
telangiectasia-like disorder (ATLD), ataxia oculomotor apraxia type 1 (AOA1) and ataxia 
oculomotor apraxia type 2A (AOA2) are a subgroup of the autosomal recessive 
spinocerebellar ataxias characterized by cerebellar atrophy and oculomotor apraxia. The 
progressive neurodegeneration described in AT and ATLD is due to mutations in genes 
encoding for ATM and Mre11, respectively. ATM recognizes and signals DNA DSBs to the 
cell cycle checkpoints and the DNA repair machinery. The Mre11 DNA repair complex, 
composed of Rad50, Mre11 and Nbs1 proteins, is involved in DNA damage recognition, 
DNA repair, and initiating cell cycle checkpoints. ATM and the Mre11 complex combine to 
recognize and signal DNA DSBs. AOA1 is caused by mutations in the gene encoding 
aprataxin (APTX), a nuclear protein that interacts with several DNA repair proteins, 
including XRCC1, Polǃ, DNA ligase III, PARP-1, and p53. It functions in the endprocessing 
of DNA SSBs removing 3′-phosphate, 5′-phosphate, and 3′-phosphoglycolate ends. AOA2 is 
caused by autosomal recessive mutations in the gene encoding senataxin (SETX). SETX is a 
member of the superfamily I DNA/RNA helicases, likely involved in oxidative DNA 
damage response. SETX mutations have been also linked to juvenile ALS. Overall, 
spinocerebellar ataxias deficient in DNA damage responses represent the most robust set of 
data linking mutations in DNA repair genes to neurodegeneration (Gueven et al., 2007; 
Martin, 2008). 
6.2 Huntington’s disease 
Huntington’s disease (HD) is a progressive neurodegenerative disorder resulting in 
cognitive impairment, choreiform movements and death which usually occurs 15–20 years 
after the onset of the symptoms. The disease is also characterized by psychiatric and 
behavioural disturbances. HD is an autosomal dominant disorder caused by a CAG repeat 
expansion within exon 1 of the gene encoding for huntingtin (IT15) on chromosome 4. In the 
normal population the number of CAG repeats is maintained below 35, while in individuals 
affected by HD it ranges from 35 to more than 100, resulting in an expanded polyglutamine 
segment in the protein. Age at onset of the disease is inversely correlated with the CAG 
repeat length; moreover the length of the expanded polyglutamine segment seems to be 
related to the rate of clinical progression of neurological symptoms and to the progression of 
motor impairment, but not to psychiatric symptoms. Somatic CAG repeat expansion in the 
gene encoding for huntingtin has been observed in several HD tissues, including the 
striatum which is the region most affected by the disease and the OGG1 protein has been 
involved in somatic CAG repeat expansion in HD, suggesting that it might contribute to 
disease age at onset (Kovtun et al. 2007). We recently observed a weak borderline 
association between the OGG1 Ser326Cys polymorphism and HD age at onset in a small 
group of 91 HD subjects (Coppedè et al. 2010d). However, replication of the study in a 
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cohort of more than 400 HD individuals failed to confirm the association between OGG1 
Ser326Cys and HD age at onset (Taherzadeh-Fard et al., 2010).  
6.3 Multiple sclerosis 
Multiple sclerosis (MS) has been classically regarded as an inflammatory demyelinating 
disease of the central nervous system. In recent years, it is also becoming increasingly apparent 
that there is a significant neurodegenerative component in the disease (Moore, 2010). MS is a 
complex autoimmune disease with a prominent genetic component. The primary genetic risk 
factor is the human leukocyte antigen (HLA)-DRB1*1501 allele; however, much of the 
remaining genetic contribution to MS remains to be elucidated. Briggs and collaborators 
screened 1,343 MS cases and 1,379 healthy controls of European ancestry for a total of 485 
single nucleotide polymorphisms within 72 genes related to DNA repair pathways. Only a 
single nucleotide polymorphism (rs1264307) within the general transcription factor IIH 
polypeptide 4 gene (GTF2H4), a nucleotide excision repair gene, was significantly associated 
with MS risk (OR = 0.7) after correcting for multiple testing. However, using a nonparametric 
approach comprising the Random Forests and CART algorithms, authors observed evidence 
for a predictive relation for MS based on 9 variants in nucleotide excision repair (rs4134860, 
rs2974754, rs7783714, rs4134813, rs2957873 and rs4150454), homologous recombination 
(rs9562605), and nonhomologous end-joining genes (rs9293329 and rs1231201). Specifically, 
variants within nucleotide excision repair genes were most prominent among predictors of MS 
(Briggs et al., 2010). Variants of DNA repair genes, particularly BRCA2 (rs1801406) and XRCC5 
(rs207906), might also increase the risk for the development of secondary acute promyelocytic 
leukemia in MS patients (Hasan et al., 2011). 
6.4 Diseases caused by mutations of NER genes 
Xeroderma pigmentosum (XP), Cockayne’s syndrome (CS) and trichothiodystropy (TTD) 
represent a clinically heterogeneous group of progeroid syndromes characterized by defects in 
NER proteins. A subset of these patients exhibits neurological dysfunction and 
neurodegeneration, and many XP patients have high cancer predisposition, thus linking DNA 
repair defects to premature aging, cancer and neurodegeneration. Several studies performed in 
mice, as well as in cell cultures, suggest that neurodegeneration in XP and CS patients might 
arise as a consequence of impaired repair of oxidative DNA lesions caused by mutations of 
NER genes. Details are provided in our recent updated review (Coppedè & Migliore, 2010) 
7. Conclusions 
The present chapter describes the current knowledge concerning DNA repair genes and 
neurodegeneration. Studies in ataxias (section 6.1) have undoubtedly linked genes involved 
in DNA repair to neurodegeneration. These observations, alongside with evidence of 
increased DNA damage in affected brain regions, have driven researchers to search for 
variant and polymorphisms of DNA repair genes in major neurodegenerative diseases such 
as AD, ALS and PD. Studies in sporadic late onset AD patients (Section 3) suggest that 
common polymorphisms of BER genes, namely OGG1 Ser326Cys, APEX1 Asp148Glu, and 
XRCC1 (Arg194Trp, Arg280His and Arg399Gln) are unlikely to represent major AD risk 
factors. However, further studies are required to replicate and clarify the associations 
observed between PARP-1 haplotypes and disease risk. Moreover, the power of these 
studies was limited by the sample size of case-control groups (Table 2), gene-gene 
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interactions were missing, and only common polymorphisms have been included with little 
or no attention paid to rare gene variants. Concerning ALS, although results are still 
inconclusive, some studies performed in northern Europe suggest a possible association 
between the APEX1 Asp148Glu polymorphism and disease risk, the OGG1 Ser326Cys 
polymorphism was associated with increased ALS risk in Italy, and XRCC1 variants gave 
conflicting results in different populations (Table 3). Overall, these studies (Section 4) 
suggest the need of further investigation aimed at addressing the contribution of 
haplotypes, gene-gene and gene-environment interactions. There is evidence for a 
contribution of POLG1 mutations in PD, and parkin seems to be involved in mtDNA repair, 
thus strengthening  the contribution of mtDNA mutations to disease pathogenesis (Section 
5). Increasing evidence suggests that BER proteins might be involved in CAG repeat 
expansion in somatic cells of HD individuals (Section 6.2), however studies aimed at 
addressing the possible contribution of variant of BER genes to disease age at onset are still 
in their beginnings. Recent evidence also suggests a possible contribution of NER genes in 
MS (Section 6.3), and the impaired ability to repair oxidative DNA damage might cause 
neurodegeneration observed in progeroid syndromes caused by mutations of NER genes 
(Section 6.4). In summary, increasing evidence supports a role for DNA repair genes in 
neurodegeneration, making this field a promising area for further investigation. 
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